Research | Alzheimer's Prevention Registry

You are here

Research

Leading Researcher Weighs in on Lewy Body Dementia Versus Alzheimer’s

Imagine being told you are living with Alzheimer’s disease only to discover you have been misdiagnosed and are suffering from another neurodegenerative condition. At 52 years old, Mike Belleville was diagnosed with early-onset Alzheimer’s. Several years later, he was reevaluated and learned he has Lewy body dementia (LBD), a disease many researchers believe is the second most common form of dementia, affecting an estimated 1.3 million Americans. Belleville is among a number of people who have experienced the pain of misdiagnosis and are living with what the Lewy Body Dementia Association (LBDA) calls “the most misdiagnosed form of dementia.”

Is There an Alzheimer’s Blood Test?

Could an Alzheimer’s blood test be in our near future? Short answer: possibly, yes.

Alzheimer's in extended family members increased risk of disease, study shows

It’s well established that having a parent or sibling with Alzheimer’s increases a person’s risk of developing the disease. A new, NIA-supported study shows that even in the absence of close family members with Alzheimer’s, having extended family members with the disease increased a person’s risk. The findings, published April 9 in Neurology, could have implications for assessing risk using a broader view of family history.

Alzheimer’s drugs cost seven times more than cancer drugs to develop

The last US-approved Alzheimer’s drug—which was a new package of two existing drugs in a single pill—received the green light in 2003. In the nearly two decades since, there have been countless failures to develop any new treatment for the most common form of dementia. 

Alzheimer’s drugs cost seven times more than cancer drugs to develop

The last US-approved Alzheimer’s drug—which was a new package of two existing drugs in a single pill—received the green light in 2003. In the nearly two decades since, there have been countless failures to develop any new treatment for the most common form of dementia. 

Primary care providers should screen seniors for decline in memory and thinking skills

The Alzheimer’s Association’s latest Facts and Figures report found most seniors are not evaluated for memory and thinking problems by their primary care providers. Learn more about the role these doctors can play in the early identification of cognitive decline and the importance of talking with your doctor if you have concerns.

So Far, Just One Thing Has 'Experimental Support' In Staving Off Alzheimer's

“I tell people to go to the gym three to four times a week if they want to prevent Alzheimer’s.” And that along with a healthy diet may well be all we have for now in the wake of so many failed attempts at treating or curing the disease. Still, scientists like Dr. R. Scott Turner, who directs the Memory Disorders Program at Georgetown University Medical Center, are far from giving up the fight.

It seems like Alzheimer's but peek into the brain shows a mimic

Some people told they have Alzheimer’s may instead have a newly identified mimic of the disease — and scientists say even though neither is yet curable, it’s critical to get better at telling different kinds of dementia apart.

Alzheimer’s Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer’s Disease

The Alzheimer’s Clinical Trials Consortium (ACTC) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) and the investigational anti-amyloid beta (Aβ) protofibril antibody BAN2401, which are currently being evaluated as treatments for early Alzheimer’s disease (AD), have been selected by the ACTC as treatments to be evaluated in upcoming clinical studies targeting primary prevention (A3 Study) and secondary prevention (A45 Study) of AD. These studies will be conducted with funding from various sources including the United States National Institute on Aging (NIA), part of the National Institutes of Health, and Eisai.